How the PanCAN master protocol could promote innovation in pancreatic cancer
With the launch of Precision Promise, pancreatic cancer is the latest indication to secure an adaptive platform trial
With the launch of Precision Promise, pancreatic cancer is the latest indication to secure an adaptive platform trial.
The motivation for launching the first adaptive platform trial in pancreatic cancer is to stimulate therapeutic innovation in an indication sorely in need of new ideas. The hope of the non-profit leading the study is that by changing the economics of drug development it can engage more biopharmas, and more patients, in the process.
On Tuesday, the Pancreatic Cancer Action Network (PanCAN) announced the long-anticipated launch of the Precision Promise master protocol trial, adding pancreatic cancer to a slowly growing list of indications being addressed with adaptive platform trials.
The Precision Promise trial, which will be